The Efficacy and Safety of Docetaxel Plus Prednisone with or without Lenalidomide in Patients with Castrate-Resistant Prostate Cancer: The MAINSAIL Trial

Article Information

DOI 
http://dx.doi.org/10.1177/155989771215006
Published By 
SAGE Publications
Print ISSN 
1559-8977
Online ISSN 
2155-756X
Copyright & Usage 
© 2012 MD Conference Express®

Author Information

  1. Phil Vinall
  1. Daniel P. Petrylak, MD
    1. Yale Cancer Center, New Haven, Connecticut, USA
View Full Text

Article usage

AbstractFullPDF
Apr 2015600
May 2015100
Jul 2015100
Aug 2015111
Sep 2015100
Oct 2015132
Nov 2015100
Total1243

Note: Article usage statistics are calculated and reported monthly.

Cited By...

  • No citing articles found.
Back to top

Tools

View Full Page PDF
Citation Tools
Email
The Efficacy and Safety of Docetaxel Plus Prednisone with or without Lenalidomide in Patients with Castrate-Resistant Prostate Cancer: The MAINSAIL Trial
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

Reproductive Cancers
Oncology Clinical Trials